Vertex Trikafta Approved As First Triple Combo For Cystic Fibrosis With $311,503 Price Tag
The US FDA cleared the combination in just three months for patients with the most common genetic mutation. Company sets price above double regimen Symdeko, but in line with trailblazer Kalydeco.
You may also be interested in...
Six of seven mid-sized companies enjoyed valuation increases over the first quarter, with four firms up by 7.5% or more. Some are benefiting from direct involvement in addressing the COVID-19 pandemic.
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.
After three years as the pharma bogeyman, Vertex has agreed a deal in England. So what purpose did the stand-off serve?